A. S.
- Country
- Spain
- Department
- Hematology
Research Overview
Data & Insights
Has run more than one trial at 0 of 16 partner sites.
Specializations
Acute Myeloid Leukemia & Myelodysplastic Syndromes
Focused on the biology and therapeutic strategies for acute myeloid leukemia and myelodysplastic syndromes, including high‑risk molecular subsets.
- Acute myeloid leukemia
- Myelodysplastic syndromes
- IDH1‑mutated AML
- NPM1‑mutated AML
- MRD‑guided therapy
Collaborates with the Institut Català d'Oncologia to integrate novel targeted agents into standard regimens.
Lymphoid Malignancies
Investigates a spectrum of B‑cell and T‑cell neoplasms, emphasizing precision medicine in chronic lymphocytic leukemia and aggressive lymphomas.
- Chronic lymphocytic leukemia
- Follicular lymphoma
- Mantle cell lymphoma
- Diffuse large B‑cell lymphoma
- Peripheral T‑cell lymphoma
Leverages molecular profiling to guide kinase inhibitor and immunotherapy trials.
Multiple Myeloma & Plasma Cell Disorders
Dedicated to advancing treatment for multiple myeloma, including high‑risk cytogenetic disease and post‑transplant maintenance.
- Multiple myeloma
- AL amyloidosis
- High‑risk myeloma
- CAR‑T cell therapy for plasma cells
- MRD‑negative remission
Integrates novel immunomodulatory drugs and antibody‑drug conjugates into therapeutic algorithms.
Stem Cell Transplantation & Graft‑Versus‑Host Disease
Focuses on optimizing allogeneic hematopoietic stem cell transplantation and managing graft‑versus‑host disease in high‑risk patients.
- Allogeneic stem cell transplantation
- Acute graft‑versus‑host disease
- Chronic graft‑versus‑host disease
- Transplant‑related mortality reduction
- Immune reconstitution strategies
Implements novel prophylactic and therapeutic agents to improve post‑transplant outcomes.
Emerging Targeted & Immunotherapies
Explores cutting‑edge approaches such as CAR‑T cells, checkpoint inhibition, and mutation‑specific inhibitors across hematologic and selected solid tumors.
- CAR‑T cell therapy
- PD‑1/PD‑L1 checkpoint inhibitors
- KRAS‑G12C inhibitors
- BTK inhibition
- FGFR‑targeted agents
Supports translational studies linking molecular biomarkers to therapeutic response.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.